HK1243407A1 - Ripk2抑制劑及用其治療癌症的方法 - Google Patents

Ripk2抑制劑及用其治療癌症的方法

Info

Publication number
HK1243407A1
HK1243407A1 HK18102804.2A HK18102804A HK1243407A1 HK 1243407 A1 HK1243407 A1 HK 1243407A1 HK 18102804 A HK18102804 A HK 18102804A HK 1243407 A1 HK1243407 A1 HK 1243407A1
Authority
HK
Hong Kong
Prior art keywords
same
treating cancer
ripk2 inhibitors
ripk2
inhibitors
Prior art date
Application number
HK18102804.2A
Other languages
English (en)
Inventor
Radoslaw Laufer
Grace Ng
Richard Brokx
Heinz W Pauls
Sze-Wan Li
Jacqueline M Mason
Mark R Bray
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of HK1243407A1 publication Critical patent/HK1243407A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
HK18102804.2A 2014-10-27 2018-02-27 Ripk2抑制劑及用其治療癌症的方法 HK1243407A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068985P 2014-10-27 2014-10-27
PCT/CA2015/051024 WO2016065461A1 (en) 2014-10-27 2015-10-09 Ripk2 inhibitors and method of treating cancer with same

Publications (1)

Publication Number Publication Date
HK1243407A1 true HK1243407A1 (zh) 2018-07-13

Family

ID=55856305

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18102804.2A HK1243407A1 (zh) 2014-10-27 2018-02-27 Ripk2抑制劑及用其治療癌症的方法

Country Status (7)

Country Link
US (3) US10239881B2 (zh)
EP (1) EP3212652B1 (zh)
JP (1) JP6545262B2 (zh)
CN (1) CN107454899B (zh)
CA (1) CA2964282C (zh)
HK (1) HK1243407A1 (zh)
WO (1) WO2016065461A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107454899B (zh) 2014-10-27 2020-05-29 大学健康网络 Ripk2抑制剂及用其治疗癌症的方法
PE20190979A1 (es) 2016-09-15 2019-07-09 Boehringer Ingelheim Int Compuestos de heteroarilcarboxamida como inhibidores de ripk2
WO2018052773A1 (en) * 2016-09-15 2018-03-22 Boehringer Ingelheim International Gmbh Pyridine and pyrazine compounds as inhibitors of ripk2
JP6965083B2 (ja) * 2017-10-04 2021-11-10 公益財団法人微生物化学研究会 化合物、及び発光化合物
TW202039481A (zh) * 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑
CN114957280A (zh) * 2021-12-31 2022-08-30 成都赜灵生物医药科技有限公司 噻吩[2,3-d]嘧啶衍生物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1265897A1 (en) * 2000-03-20 2002-12-18 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
EP1182263A1 (en) 2000-08-11 2002-02-27 Evotec OAI AG Process for detecting threonine/serine kinase activity
US6426221B1 (en) 2001-08-01 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of RIP2 expression
US20030134310A1 (en) 2001-11-13 2003-07-17 Cujec Thomas P. Cellular kinase targets and inhibitors, and methods for their use
CA2703600C (en) 2007-11-15 2017-04-25 Ym Biosciences Australia Pty Ltd Fused thieno or pyrrolo pyrimidine heterocyclic compounds and use thereof as jak1, jak2, and/or jak3 inhibitors
CA2730357A1 (en) 2008-08-16 2010-02-25 Genetech, Inc. Azaindole inhibitors of iap
WO2010046215A2 (en) 2008-10-21 2010-04-29 Syngenta Participations Ag Diaza-indole derivatives and their use as fungicides
US20110207736A1 (en) * 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
ES2552977T3 (es) 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
US8889684B2 (en) * 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
AU2012225735B2 (en) 2011-03-04 2016-03-10 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
CN107454899B (zh) 2014-10-27 2020-05-29 大学健康网络 Ripk2抑制剂及用其治疗癌症的方法

Also Published As

Publication number Publication date
US20210261554A1 (en) 2021-08-26
US20180282335A1 (en) 2018-10-04
CN107454899A (zh) 2017-12-08
CN107454899B (zh) 2020-05-29
EP3212652B1 (en) 2021-02-17
CA2964282C (en) 2023-03-07
EP3212652A4 (en) 2018-04-25
JP2017531686A (ja) 2017-10-26
US10239881B2 (en) 2019-03-26
WO2016065461A1 (en) 2016-05-06
US20190225617A1 (en) 2019-07-25
CA2964282A1 (en) 2016-05-06
EP3212652A1 (en) 2017-09-06
JP6545262B2 (ja) 2019-07-17
US10875863B2 (en) 2020-12-29

Similar Documents

Publication Publication Date Title
IL283353A (en) hpk1 inhibitors and methods of using them
HK1251408A1 (zh) 治療癌症的方法
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
ZA201804227B (en) Methods of treating cancer
ZA201703075B (en) Substituted chromanes and method of use
EP3233089A4 (en) Method of treating cancer with cgamp or cgasmp
HK1248552A1 (zh) 使用川地匹坦的治療方法
HK1243407A1 (zh) Ripk2抑制劑及用其治療癌症的方法
PT3265106T (pt) Novo método para tratamento e prognóstico do cancro
PL3148340T3 (pl) Urządzenie i sposób dla pozycjonowania krewetek
IL255012A0 (en) Preparations and methods for treating skin conditions
PL3268376T3 (pl) Inhibitory enolazy i sposoby leczenia je wykorzystujące
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201416797D0 (en) Contianer and method of use thereof
GB201419990D0 (en) Hprseshoe and method of manufacture

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: HONG KONG INTELLECTUAL PROPERTY JOURNAL DATED 26.11.2021 CORRECTED DATA OF SECTION 27: (73) UNIVERSITY HEALTH NETWORK 190 ELIZABETH STREET R. FRASER ELLIOTT BUILDING - ROOM 1S-417 TORONTO, ONTARIO M5G 2C4 CANADA